<p>丹納赫公司（Danaher Corporation，DHR）在最近幾個月經歷了過山車般的波動，由於第四季度業績低於預期以及生物科技和製藥行業需求疲軟，其股價遭受了重大打擊。然而，分析師們現在建議該股已經下跌到足夠的程度，可能是時候買入了。讓我們深入瞭解細節，看看這是否是一個合理的投資策略。</p>
<p><img src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-1a621c912f820002.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-1a621c912f820002.png"/></p>
<p>丹納赫最近的財務表現喜憂參半。該公司報告 2024 年第四季度淨收益為 11 億美元，或每股稀釋普通股收益 1.49 美元，非 GAAP 調整後的每股稀釋淨收益為 2.14 美元。收入同比增長 2.0%，達到 65 億美元，非 GAAP 核心收入增長 1.0%。儘管這些數字顯示出一定的增長，但仍未達到華爾街的預期，導致股價下跌。</p>
<p>業績未達預期的主要原因是生物科技和製藥客户對藥物開發所需工具和服務的需求疲軟。這一趨勢令人擔憂，因為它表明生命科學和診斷領域可能出現放緩，而這些正是丹納赫的核心業務。然而，考慮更廣泛的背景和公司的長期前景是至關重要的。</p>
<p>丹納赫在提供穩健的財務業績和保持強勁的利潤率方面有着良好的記錄。2022 年，該公司報告第四季度淨收益同比增長 25.0%，全年增長 13.5%。這一歷史表現表明，丹納赫具備在困難時期應對挑戰的韌性和戰略重點。</p>
<p>此外，丹納赫強勁的現金流狀況使其能夠投資於增長機會，通過分紅和股票回購向股東返還資本，並保持財務靈活性。該公司在 2024 年執行了 45 億美元的股票回購，展示了其向股東回饋價值的承諾。此外，丹納赫將季度分紅提高至每股 0.32 美元，使其成為收入導向投資者的一個有吸引力的選擇。</p>
<p>展望未來，丹納赫對 2025 年第一季度和全年的展望表明，公司預計非 GAAP 核心收入將同比增長約 3%。這一積極展望表明，丹納赫對其未來收入增長和財務健康的能力充滿信心。</p>
<p>然而，考慮丹納赫在不久的將來可能面臨的潛在風險和挑戰是至關重要的。市場波動、生物科技和製藥行業需求疲軟以及監管風險可能會影響公司的長期增長前景和股價表現。此外，丹納赫對生命科學和診斷的依賴、收購整合以及貨幣波動也構成潛在風險。</p>
<p>總之，儘管丹納赫最近的財務表現令人失望，但公司的強大基本面、穩健的現金流以及對未來增長的積極展望使其成為一個有吸引力的投資選擇。分析師們建議在當前價格水平買入該股，表明市場對最近的業績未達預期反應過度，股價已經下跌到足夠的程度，呈現出買入機會。然而，投資者在做出投資決策之前應仔細考慮潛在的風險和挑戰。</p>

丹納赫

<p>丹納赫公司的股票因第四季度業績低於預期以及生物技術行業需求疲軟而下跌。分析師建議現在可能是買入的時機，指出丹納赫強勁的財務歷史、穩健的現金流以及對 2025 年的積極展望，預計收入將增長。儘管近期表現令人失望，但公司通過回購和分紅對股東價值的承諾使其成為一個有吸引力的選擇。然而，潛在風險包括市場波動和行業需求挑戰。投資者在決定投資之前應權衡這些因素</p>

<p>Danaher Corporation (DHR) has been on a rollercoaster ride in recent months, with its stock price taking a significant hit due to weaker-than-expected fourth-quarter earnings and soft demand in the biotech and pharmaceutical sectors. However, analysts are now suggesting that the stock has fallen far enough and that it might be time to buy. Let's dive into the details and see if this is a sound investment strategy.</p>
<div class="lb-trans"><p>丹納赫公司（Danaher Corporation，DHR）在最近幾個月經歷了過山車般的波動，由於第四季度業績低於預期以及生物科技和製藥行業需求疲軟，其股價遭受了重大打擊。然而，分析師們現在建議該股已經下跌到足夠的程度，可能是時候買入了。讓我們深入瞭解細節，看看這是否是一個合理的投資策略。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-1a621c912f820002.png" alt="" original-src="https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-1a621c912f820002.png"/></p>
<p>Danaher's recent financial performance has been a mixed bag. The company reported net earnings of $1.1 billion, or $1.49 per diluted common share, for the fourth quarter of 2024, with non-GAAP adjusted diluted net earnings per common share at $2.14. Revenues increased by 2.0% year-over-year to $6.5 billion, and non-GAAP core revenue increased by 1.0%. While these numbers show some growth, they fell short of Wall Street's expectations, leading to a decline in the stock price.</p>
<div class="lb-trans"><p>丹納赫最近的財務表現喜憂參半。該公司報告 2024 年第四季度淨收益為 11 億美元，或每股稀釋普通股收益 1.49 美元，非 GAAP 調整後的每股稀釋淨收益為 2.14 美元。收入同比增長 2.0%，達到 65 億美元，非 GAAP 核心收入增長 1.0%。儘管這些數字顯示出一定的增長，但仍未達到華爾街的預期，導致股價下跌。</p>
</div><p>The primary reason for the earnings miss was soft demand for tools and services used in drug development by biotech and pharmaceutical clients. This trend is concerning, as it indicates a potential slowdown in the life sciences and diagnostics sectors, which are Danaher's core businesses. However, it's essential to consider the broader context and the company's long-term prospects.</p>
<div class="lb-trans"><p>業績未達預期的主要原因是生物科技和製藥客户對藥物開發所需工具和服務的需求疲軟。這一趨勢令人擔憂，因為它表明生命科學和診斷領域可能出現放緩，而這些正是丹納赫的核心業務。然而，考慮更廣泛的背景和公司的長期前景是至關重要的。</p>
</div><p>Danaher has a strong track record of delivering solid financial results and maintaining robust profit margins. In 2022, the company reported a 25.0% year-over-year increase in net earnings for the fourth quarter and a 13.5% year-over-year increase for the full year. This historical performance suggests that danaher has the resilience and strategic focus to navigate through challenging times.</p>
<div class="lb-trans"><p>丹納赫在提供穩健的財務業績和保持強勁的利潤率方面有着良好的記錄。2022 年，該公司報告第四季度淨收益同比增長 25.0%，全年增長 13.5%。這一歷史表現表明，丹納赫具備在困難時期應對挑戰的韌性和戰略重點。</p>
</div><p>Moreover, Danaher's strong cash flow position allows it to invest in growth opportunities, return capital to shareholders through dividends and share buybacks, and maintain financial flexibility. The company executed a $4.5 billion share buyback in 2024, demonstrating its commitment to returning value to shareholders. Additionally, Danaher increased its quarterly dividend to $0.32 per share, making it an attractive option for income-focused investors.</p>
<div class="lb-trans"><p>此外，丹納赫強勁的現金流狀況使其能夠投資於增長機會，通過分紅和股票回購向股東返還資本，並保持財務靈活性。該公司在 2024 年執行了 45 億美元的股票回購，展示了其向股東回饋價值的承諾。此外，丹納赫將季度分紅提高至每股 0.32 美元，使其成為收入導向投資者的一個有吸引力的選擇。</p>
</div><p>Looking ahead, Danaher's outlook for the first quarter and full year 2025 indicates that the company expects non-GAAP core revenue to increase by approximately 3% year-over-year. This positive outlook suggests that Danaher is confident in its ability to grow its revenue and maintain its financial health in the future.</p>
<div class="lb-trans"><p>展望未來，丹納赫對 2025 年第一季度和全年的展望表明，公司預計非 GAAP 核心收入將同比增長約 3%。這一積極展望表明，丹納赫對其未來收入增長和財務健康的能力充滿信心。</p>
</div><p>However, it's essential to consider the potential risks and challenges that Danaher may face in the near future. Market volatility, soft demand in the biotech and pharmaceutical sectors, and regulatory risks could impact the company's long-term growth prospects and stock performance. Additionally, Danaher's dependency on life sciences and diagnostics, integration of acquisitions, and currency fluctuations pose potential risks.</p>
<div class="lb-trans"><p>然而，考慮丹納赫在不久的將來可能面臨的潛在風險和挑戰是至關重要的。市場波動、生物科技和製藥行業需求疲軟以及監管風險可能會影響公司的長期增長前景和股價表現。此外，丹納赫對生命科學和診斷的依賴、收購整合以及貨幣波動也構成潛在風險。</p>
</div><p>In conclusion, while Danaher's recent financial performance has been disappointing, the company's strong fundamentals, robust cash flow, and positive outlook for future growth make it an attractive investment option. Analysts' recommendations to buy the stock at its current price level suggest that the market has overreacted to the recent earnings miss, and the stock has fallen far enough to present a buying opportunity. However, investors should carefully consider the potential risks and challenges before making an investment decision.</p>
<div class="lb-trans"><p>總之，儘管丹納赫最近的財務表現令人失望，但公司的強大基本面、穩健的現金流以及對未來增長的積極展望使其成為一個有吸引力的投資選擇。分析師們建議在當前價格水平買入該股，表明市場對最近的業績未達預期反應過度，股價已經下跌到足夠的程度，呈現出買入機會。然而，投資者在做出投資決策之前應仔細考慮潛在的風險和挑戰。</p>
</div>

丹納赫股票已經跌得夠多了。分析師建議現在買入